The primary benefits of ivosidenib include its ability to specifically target mutant IDH1 enzymes, which provides a more tailored approach to treating cancers with this particular mutation. Clinical trials have shown that ivosidenib can induce complete remissions and significantly reduce 2-HG levels in patients. This targeted approach often results in fewer side effects compared to traditional cytotoxic chemotherapies.
